Previous 10 | Next 10 |
The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2020 Q4 - Results - Earnings Call Presentation
Cerevel Therapeutics Holdings, Inc. (CERE) Q4 2020 Earnings Conference Call March 24, 2021 08:00 ET Company Participants Matt Calistri - Vice President, Investor Relations Tony Coles - Chief Executive Officer Ray Sanchez - Chief Medical Officer John Renger - Chief Scientific Officer Kathy Yi ...
Cerevel Therapeutics (CERE): Q4 GAAP EPS of -$0.27.Cash and cash equivalents of $383.6MPress Release For further details see: Cerevel Therapeutics reports Q4 results
Data readout of Phase 1b trial of CVL-231 in patients with schizophrenia now expected mid-year 2021 IND submitted for CVL-871 in dementia-related apathy Conference call and webcast scheduled for today at 8:00 AM EDT CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE)...
CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that Chairperson and Chief Executive Officer, Tony Coles, M.D. will participate...
The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with this event. For further details see: Cerevel Therapeutics Holdings (CERE) Investor Presentation - Slideshow
CAMBRIDGE, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2020 financial results on Wedn...
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health...
Darigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric Modulator Company Expects to File U.S. IND Applications in 2021 for PDE4B and Kappa Opioid Receptor Agonist Preclinical Programs Live webcast today from 9:00 to 11:0...
Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs Live webcast scheduled for Thursday, January 28 from 9:00 to 11:00 a.m. EST CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cerevel Therap...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are enco...